Clearmind Medicine Receives Approval for Phase I/II Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 22 hours ago
0mins
Source: Newsfilter
- Clinical Trial Approval: Clearmind Medicine Inc. announced that its CMND-100 Phase I/II clinical trial has received approval from the Johns Hopkins Medicine Institutional Review Board, marking a significant advancement in the company's efforts to address alcohol use disorder and is expected to facilitate the smooth progression of subsequent research.
- Research Phase Progress: This approval allows the company to proceed with Parts B and C of the trial, reflecting the solid foundation laid by Clearmind's earlier successes at one of the world's leading clinical research institutions, which is crucial for future studies.
- CEO Commentary: CEO Dr. Adi Zuloff-Shani stated that this IRB approval represents an important step in the company's clinical development program, demonstrating confidence in the potential of its non-hallucinogenic MEAI-based candidate for patients suffering from alcohol use disorder, thereby enhancing market expectations for its products.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to seek additional patents in the future to strengthen its competitive position in the neuroplastogen drug sector and ensure the market standing of its innovative therapeutics.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMND?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMND
About CMND
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Multiple Companies See Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw its stock price jump nearly 80% to $9.11 on Tuesday as it advances the development of its Ebola PCR assay, which is expected to significantly enhance the company's competitiveness in the molecular diagnostics market.
- NRXP Regulatory Catalysts: NRx Pharmaceuticals Inc. (NRXP) shares rose over 30% to $4.31, driven by the anticipation of a New Drug Application submission to the FDA, which is expected to boost the company's market share in the treatment of suicidal depression.
- ECOR Revenue Growth: electroCore Inc. (ECOR) reported a 43% revenue increase in Q1, with expectations of a 30% rise in annual revenue compared to 2025, leading to a 33.58% stock price increase, indicating strong performance in the bioelectronic medicine sector.
- OTLK Regulatory Progress: Outlook Therapeutics Inc. (OTLK) shares jumped over 29% to $0.40 following positive regulatory developments regarding LYTENAVA, with plans to resubmit the Biologics License Application in June 2026, reflecting a strategic shift in their approach to FDA engagement.
See More
Clearmind Medicine Receives Approval for Phase I/II Clinical Trial
- Clinical Trial Approval: Clearmind Medicine Inc. announced that its CMND-100 Phase I/II clinical trial has received approval from the Johns Hopkins Medicine Institutional Review Board, marking a significant advancement in the company's efforts to address alcohol use disorder and is expected to facilitate the smooth progression of subsequent research.
- Research Phase Progress: This approval allows the company to proceed with Parts B and C of the trial, reflecting the solid foundation laid by Clearmind's earlier successes at one of the world's leading clinical research institutions, which is crucial for future studies.
- CEO Commentary: CEO Dr. Adi Zuloff-Shani stated that this IRB approval represents an important step in the company's clinical development program, demonstrating confidence in the potential of its non-hallucinogenic MEAI-based candidate for patients suffering from alcohol use disorder, thereby enhancing market expectations for its products.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to seek additional patents in the future to strengthen its competitive position in the neuroplastogen drug sector and ensure the market standing of its innovative therapeutics.
See More
Clearmind Medicine to Execute 1-for-10 Reverse Stock Split
- Reverse Stock Split Plan: Clearmind Medicine has announced a 1-for-10 reverse stock split effective May 21, 2026, aimed at regaining compliance with the Nasdaq Minimum Bid Price Rule, which will reduce the number of issued and outstanding common shares from 10,190,337 to approximately 1,019,033, thereby increasing the share price to meet compliance requirements.
- Market Reaction: Following the reverse split announcement, Clearmind's shares fell by 20% in premarket trading, indicating market concerns about the company's future prospects, which could undermine investor confidence and exacerbate liquidity risks.
- Compliance Pressure: This reverse stock split is a response to Nasdaq compliance pressures, as failure to restore the share price within the stipulated time frame could lead to delisting risks, posing significant challenges to the company's long-term development.
- Strategic Implications: By implementing the reverse stock split, Clearmind aims to attract more institutional investors by increasing its share price, thereby enhancing market recognition and creating conditions for future financing, although short-term price volatility may increase.
See More
Clearmind Announces 1-for-10 Reverse Stock Split
- Reverse Stock Split: Clearmind Medicine Inc. announced a 1-for-10 reverse stock split effective May 21, 2026, aimed at regaining compliance with Nasdaq's Minimum Bid Price Rule, which will reduce the number of outstanding shares from 10,190,337 to approximately 1,019,033, thereby potentially increasing the share price to meet listing requirements.
- Board Approval: The reverse split was approved by the company's board on March 18, 2026, reflecting proactive measures taken in response to stock price pressures, aimed at boosting investor confidence and maintaining its position in the capital markets.
- No Fractional Shares: Following the reverse split, no fractional shares will be issued, with all fractions rounded up to the nearest whole share, simplifying the shareholder structure and reducing potential shareholder confusion.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to seek additional patents in the future to enhance its market competitiveness in the non-hallucinogenic drug sector, demonstrating the company's commitment to innovation and intellectual property.
See More
Clearmind Medicine Engages in Federal Policy Summit
- Summit Participation: Clearmind Medicine's CEO, Dr. Adi Zuloff-Shani, was appointed as a delegate to the 2026 Federal Policy Summit held on May 14 in Washington, D.C., aimed at fostering dialogue between the biopharma industry and policymakers to advance the responsible development of psychedelic therapies.
- Clinical Trial Progress: Clearmind is advancing its non-hallucinogenic psychedelic candidate, currently undergoing Phase IIa clinical trials at leading institutions like Johns Hopkins and Yale, which not only showcases the company's commitment to innovative drug development but also addresses significant unmet health needs.
- Intellectual Property Strategy: Clearmind holds 19 patent families and 31 granted patents, with plans to seek additional patents as warranted, indicating a proactive approach to intellectual property that aims to enhance its market competitiveness and technological barriers.
- Industry Collaboration and Impact: The summit brought together key figures from the U.S. Congress and global biopharma CEOs, emphasizing the importance of cross-sector collaboration, and Clearmind's participation may pave the way for future policy support and market access.
See More
Clearmind's Positive Clinical Trial Results May Support Breakthrough Therapy Designation
- Clinical Trial Progress: Clearmind Medicine is evaluating its candidate CMND-100 for eligibility for the FDA's Breakthrough Therapy Designation based on positive results from its ongoing Phase I/IIa clinical trial for Alcohol Use Disorder, indicating significant therapeutic potential that could open new market opportunities for the company.
- Policy Support: The recent Executive Order signed by President Trump accelerates FDA review processes for certain breakthrough therapies, providing favorable conditions for CMND-100's application and further enhancing Clearmind's strategic position in the competitive biotech market.
- Market Demand: Alcohol Use Disorder represents a serious health issue affecting millions globally with limited treatment options, and the successful development of CMND-100 could address this substantial unmet medical need, potentially yielding significant economic benefits for the company.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to continue expanding its intellectual property portfolio to support drug development and commercialization strategies, ensuring a competitive edge in future market dynamics.
See More
Multiple Companies See Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw its stock price jump nearly 80% to $9.11 on Tuesday as it advances the development of its Ebola PCR assay, which is expected to significantly enhance the company's competitiveness in the molecular diagnostics market.
- NRXP Regulatory Catalysts: NRx Pharmaceuticals Inc. (NRXP) shares rose over 30% to $4.31, driven by the anticipation of a New Drug Application submission to the FDA, which is expected to boost the company's market share in the treatment of suicidal depression.
- ECOR Revenue Growth: electroCore Inc. (ECOR) reported a 43% revenue increase in Q1, with expectations of a 30% rise in annual revenue compared to 2025, leading to a 33.58% stock price increase, indicating strong performance in the bioelectronic medicine sector.
- OTLK Regulatory Progress: Outlook Therapeutics Inc. (OTLK) shares jumped over 29% to $0.40 following positive regulatory developments regarding LYTENAVA, with plans to resubmit the Biologics License Application in June 2026, reflecting a strategic shift in their approach to FDA engagement.
See More
Clearmind Medicine Receives Approval for Phase I/II Clinical Trial
- Clinical Trial Approval: Clearmind Medicine Inc. announced that its CMND-100 Phase I/II clinical trial has received approval from the Johns Hopkins Medicine Institutional Review Board, marking a significant advancement in the company's efforts to address alcohol use disorder and is expected to facilitate the smooth progression of subsequent research.
- Research Phase Progress: This approval allows the company to proceed with Parts B and C of the trial, reflecting the solid foundation laid by Clearmind's earlier successes at one of the world's leading clinical research institutions, which is crucial for future studies.
- CEO Commentary: CEO Dr. Adi Zuloff-Shani stated that this IRB approval represents an important step in the company's clinical development program, demonstrating confidence in the potential of its non-hallucinogenic MEAI-based candidate for patients suffering from alcohol use disorder, thereby enhancing market expectations for its products.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to seek additional patents in the future to strengthen its competitive position in the neuroplastogen drug sector and ensure the market standing of its innovative therapeutics.
See More
Clearmind Medicine to Execute 1-for-10 Reverse Stock Split
- Reverse Stock Split Plan: Clearmind Medicine has announced a 1-for-10 reverse stock split effective May 21, 2026, aimed at regaining compliance with the Nasdaq Minimum Bid Price Rule, which will reduce the number of issued and outstanding common shares from 10,190,337 to approximately 1,019,033, thereby increasing the share price to meet compliance requirements.
- Market Reaction: Following the reverse split announcement, Clearmind's shares fell by 20% in premarket trading, indicating market concerns about the company's future prospects, which could undermine investor confidence and exacerbate liquidity risks.
- Compliance Pressure: This reverse stock split is a response to Nasdaq compliance pressures, as failure to restore the share price within the stipulated time frame could lead to delisting risks, posing significant challenges to the company's long-term development.
- Strategic Implications: By implementing the reverse stock split, Clearmind aims to attract more institutional investors by increasing its share price, thereby enhancing market recognition and creating conditions for future financing, although short-term price volatility may increase.
See More
Clearmind Announces 1-for-10 Reverse Stock Split
- Reverse Stock Split: Clearmind Medicine Inc. announced a 1-for-10 reverse stock split effective May 21, 2026, aimed at regaining compliance with Nasdaq's Minimum Bid Price Rule, which will reduce the number of outstanding shares from 10,190,337 to approximately 1,019,033, thereby potentially increasing the share price to meet listing requirements.
- Board Approval: The reverse split was approved by the company's board on March 18, 2026, reflecting proactive measures taken in response to stock price pressures, aimed at boosting investor confidence and maintaining its position in the capital markets.
- No Fractional Shares: Following the reverse split, no fractional shares will be issued, with all fractions rounded up to the nearest whole share, simplifying the shareholder structure and reducing potential shareholder confusion.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to seek additional patents in the future to enhance its market competitiveness in the non-hallucinogenic drug sector, demonstrating the company's commitment to innovation and intellectual property.
See More
Clearmind Medicine Engages in Federal Policy Summit
- Summit Participation: Clearmind Medicine's CEO, Dr. Adi Zuloff-Shani, was appointed as a delegate to the 2026 Federal Policy Summit held on May 14 in Washington, D.C., aimed at fostering dialogue between the biopharma industry and policymakers to advance the responsible development of psychedelic therapies.
- Clinical Trial Progress: Clearmind is advancing its non-hallucinogenic psychedelic candidate, currently undergoing Phase IIa clinical trials at leading institutions like Johns Hopkins and Yale, which not only showcases the company's commitment to innovative drug development but also addresses significant unmet health needs.
- Intellectual Property Strategy: Clearmind holds 19 patent families and 31 granted patents, with plans to seek additional patents as warranted, indicating a proactive approach to intellectual property that aims to enhance its market competitiveness and technological barriers.
- Industry Collaboration and Impact: The summit brought together key figures from the U.S. Congress and global biopharma CEOs, emphasizing the importance of cross-sector collaboration, and Clearmind's participation may pave the way for future policy support and market access.
See More
Clearmind's Positive Clinical Trial Results May Support Breakthrough Therapy Designation
- Clinical Trial Progress: Clearmind Medicine is evaluating its candidate CMND-100 for eligibility for the FDA's Breakthrough Therapy Designation based on positive results from its ongoing Phase I/IIa clinical trial for Alcohol Use Disorder, indicating significant therapeutic potential that could open new market opportunities for the company.
- Policy Support: The recent Executive Order signed by President Trump accelerates FDA review processes for certain breakthrough therapies, providing favorable conditions for CMND-100's application and further enhancing Clearmind's strategic position in the competitive biotech market.
- Market Demand: Alcohol Use Disorder represents a serious health issue affecting millions globally with limited treatment options, and the successful development of CMND-100 could address this substantial unmet medical need, potentially yielding significant economic benefits for the company.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to continue expanding its intellectual property portfolio to support drug development and commercialization strategies, ensuring a competitive edge in future market dynamics.
See More
